FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1867691097> ?p ?o ?g. }

• W1867691097 endingPage "40849" @default.
• W1867691097 startingPage "40836" @default.
• W1867691097 abstract "The activation of immune cells by targeting checkpoint inhibitors showed promising results with increased patient survival in distinct primary cancers. Since only limited data exist for human brain metastases, we aimed at characterizing tumor infiltrating lymphocytes (TILs) and expression of immune checkpoints in the respective tumors. Two brain metastases cohorts, a mixed entity cohort (n = 252) and a breast carcinoma validation cohort (n = 96) were analyzed for CD3+, CD8+, FOXP3+, PD-1+ lymphocytes and PD-L1+ tumor cells by immunohistochemistry. Analyses for association with clinico-epidemiological and neuroradiological parameters such as patient survival or tumor size were performed. TILs infiltrated brain metastases in three different patterns (stromal, peritumoral, diffuse). While carcinomas often show a strong stromal infiltration, TILs in melanomas often diffusely infiltrate the tumors. Highest levels of CD3+ and CD8+ lymphocytes were seen in renal cell carcinomas (RCC) and strongest PD-1 levels on RCCs and melanomas. High amounts of TILs, high ratios of PD-1+/CD8+ cells and high levels of PD-L1 were negatively correlated with brain metastases size, indicating that in smaller brain metastases CD8+ immune response might get blocked. PD-L1 expression strongly correlated with TILs and FOXP3 expression. No significant association of patient survival with TILs was observed, while high levels of PD-L1 showed a strong trend towards better survival in melanoma brain metastases (Log-Rank p = 0.0537). In summary, melanomas and RCCs seem to be the most immunogenic entities. Differences in immunotherapeutic response between tumor entities regarding brain metastases might be attributable to this finding and need further investigation in larger patient cohorts." @default.
• W1867691097 created "2016-06-24" @default.
• W1867691097 creator A5014445320 @default.
• W1867691097 creator A5014850279 @default.
• W1867691097 creator A5017640916 @default.
• W1867691097 creator A5019015173 @default.
• W1867691097 creator A5037433157 @default.
• W1867691097 creator A5055084977 @default.
• W1867691097 creator A5055425144 @default.
• W1867691097 creator A5056320938 @default.
• W1867691097 creator A5056602566 @default.
• W1867691097 creator A5058159721 @default.
• W1867691097 creator A5065083196 @default.
• W1867691097 creator A5066075003 @default.
• W1867691097 creator A5067660605 @default.
• W1867691097 creator A5072628975 @default.
• W1867691097 creator A5073545313 @default.
• W1867691097 creator A5076567865 @default.
• W1867691097 creator A5076940220 @default.
• W1867691097 creator A5077149094 @default.
• W1867691097 creator A5082470296 @default.
• W1867691097 creator A5085016405 @default.
• W1867691097 date "2015-10-16" @default.
• W1867691097 modified "2023-09-26" @default.
• W1867691097 title "Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases" @default.
• W1867691097 cites W1499633524 @default.
• W1867691097 cites W1619597457 @default.
• W1867691097 cites W1974820090 @default.
• W1867691097 cites W1976105607 @default.
• W1867691097 cites W1981876938 @default.
• W1867691097 cites W1981934675 @default.
• W1867691097 cites W1983517349 @default.
• W1867691097 cites W1984599104 @default.
• W1867691097 cites W2003579048 @default.
• W1867691097 cites W2004630197 @default.
• W1867691097 cites W2010121426 @default.
• W1867691097 cites W2013090484 @default.
• W1867691097 cites W2016789384 @default.
• W1867691097 cites W2016850781 @default.
• W1867691097 cites W2016983859 @default.
• W1867691097 cites W2028433016 @default.
• W1867691097 cites W2033672531 @default.
• W1867691097 cites W2033917892 @default.
• W1867691097 cites W2039123767 @default.
• W1867691097 cites W2041560123 @default.
• W1867691097 cites W2044433401 @default.
• W1867691097 cites W2049491375 @default.
• W1867691097 cites W2049553585 @default.
• W1867691097 cites W2051083170 @default.
• W1867691097 cites W2056535502 @default.
• W1867691097 cites W2057893793 @default.
• W1867691097 cites W2063725270 @default.
• W1867691097 cites W2066671159 @default.
• W1867691097 cites W2098506409 @default.
• W1867691097 cites W2098683355 @default.
• W1867691097 cites W2101653483 @default.
• W1867691097 cites W2103220202 @default.
• W1867691097 cites W2107484016 @default.
• W1867691097 cites W2108933323 @default.
• W1867691097 cites W2116904605 @default.
• W1867691097 cites W2118342755 @default.
• W1867691097 cites W2118471749 @default.
• W1867691097 cites W2125885282 @default.
• W1867691097 cites W2131950300 @default.
• W1867691097 cites W2141307029 @default.
• W1867691097 cites W2159040226 @default.
• W1867691097 cites W2160834915 @default.
• W1867691097 cites W2171490333 @default.
• W1867691097 cites W2560367415 @default.
• W1867691097 cites W2572174216 @default.
• W1867691097 doi "https://doi.org/10.18632/oncotarget.5696" @default.
• W1867691097 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4747372" @default.
• W1867691097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26517811" @default.
• W1867691097 hasPublicationYear "2015" @default.
• W1867691097 type Work @default.
• W1867691097 sameAs 1867691097 @default.
• W1867691097 citedByCount "99" @default.
• W1867691097 countsByYear W18676910972016 @default.
• W1867691097 countsByYear W18676910972017 @default.
• W1867691097 countsByYear W18676910972018 @default.
• W1867691097 countsByYear W18676910972019 @default.
• W1867691097 countsByYear W18676910972020 @default.
• W1867691097 countsByYear W18676910972021 @default.
• W1867691097 countsByYear W18676910972022 @default.
• W1867691097 countsByYear W18676910972023 @default.
• W1867691097 crossrefType "journal-article" @default.
• W1867691097 hasAuthorship W1867691097A5014445320 @default.
• W1867691097 hasAuthorship W1867691097A5014850279 @default.
• W1867691097 hasAuthorship W1867691097A5017640916 @default.
• W1867691097 hasAuthorship W1867691097A5019015173 @default.
• W1867691097 hasAuthorship W1867691097A5037433157 @default.
• W1867691097 hasAuthorship W1867691097A5055084977 @default.
• W1867691097 hasAuthorship W1867691097A5055425144 @default.
• W1867691097 hasAuthorship W1867691097A5056320938 @default.
• W1867691097 hasAuthorship W1867691097A5056602566 @default.
• W1867691097 hasAuthorship W1867691097A5058159721 @default.
• W1867691097 hasAuthorship W1867691097A5065083196 @default.
• W1867691097 hasAuthorship W1867691097A5066075003 @default.

• next